---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-000109"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2025-01-03T23:59:59+00:00"
generated_at: "2026-05-28T14:38:03.695948+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eton acquires Galzin (zinc acetate) for $7.2M; rare disease product for Wilson Disease

## Summary
- Acquired Galzin from Teva Pharmaceuticals for $7.0M at closing plus $0.2M for inventory.
- Will pay Teva a 10% royalty on U.S. net sales through the tenth anniversary of first commercial sale.
- Galzin is the only FDA-approved zinc maintenance therapy for Wilson Disease; <5,000 U.S. patients.
- Eton expects to assume U.S. commercialization in Q1 2025 with its metabolic sales force.
- Also acquired European rights; third party commercializes under Wilzin with Eton supplying product.

## SEC filing metadata
- accession: 0001437749-25-000109
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2025-01-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774925000109/0001437749-25-000109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774925000109/eton20241219_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-000109
- JSON: https://secwatch.observer/filing/0001437749-25-000109.json
- Plain text: https://secwatch.observer/filing/0001437749-25-000109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.